A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry

| GregoryGregory | 0 Comment
A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry
Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.

Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site

Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.

Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics

Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.

Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes

Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.

Cytokeratin 7 (Cytokeratin 7) Antibody
abx232217-100ug 100 ug
EUR 610.8

Cytokeratin 7 (Cytokeratin 7) Antibody
abx232218-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232221-100ug 100 ug
EUR 577.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232222-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx232223-100ug 100 ug
EUR 661.2

Cytokeratin 15 (Cytokeratin 15) Antibody
20-abx225265
  • EUR 444.00
  • EUR 727.20
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 50 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
abx139677-01mg 0.1 mg
EUR 427.2

Cytokeratin 8 (Cytokeratin 8) Antibody
abx139678-01mg 0.1 mg
EUR 427.2

Cytokeratin 8 (Cytokeratin 8) Antibody
20-abx134066
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
20-abx121588
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 4 (Cytokeratin 4) Antibody
20-abx121076
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
20-abx007491
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
20-abx007492
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody
20-abx009056
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
20-abx009059
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 7 (Cytokeratin 7) Antibody
20-abx009060
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody
abx010621-100ul 100 ul
EUR 493.2

Cytokeratin 8 (Cytokeratin 8) Antibody (FITC)
abx139679-01mg 0.1 mg
EUR 510

Cytokeratin antibody
10R-6655 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody
10R-6656 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody
20R-CP006 100 uL
EUR 550.8
Description: Guinea Pig polyclonal Cytokeratin antibody

Cytokeratin-18 Antibody
F50352-0.08ML 0.08 ml
EUR 140.25
Description: KRT18 is the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament family. They are expressed in single layer epithelial tissues of the body. Mutations in its gene have been linked to cryptogenic cirrhosis.

Cytokeratin-18 Antibody
F50352-0.4ML 0.4 ml
EUR 322.15
Description: KRT18 is the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament family. They are expressed in single layer epithelial tissues of the body. Mutations in its gene have been linked to cryptogenic cirrhosis.

CK18 (Cytokeratin 18)
MO47021 100 ul
EUR 418.8

CK19 (Cytokeratin 19)
MO47022 100 ul
EUR 418.8

Cytokeratin-1 Antibody
39339-100ul 100ul
EUR 468

Cytokeratin-1 Antibody
abx037856-100ug 100 ug
EUR 469.2

Cytokeratin-7 Antibody
48356-100ul 100ul
EUR 399.6

Cytokeratin-7 Antibody
48356-50ul 50ul
EUR 286.8

Cytokeratin-18 Mouse mAb
A0389-100ul 100 ul
EUR 460.8

Cytokeratin-18 Mouse mAb
A0389-200ul 200 ul
EUR 664.8

Cytokeratin-18 Mouse mAb
A0389-20ul 20 ul Ask for price

Cytokeratin-18 Mouse mAb
A0389-50ul 50 ul
EUR 318

Cytokeratin-18 Rabbit pAb
A1022-100ul 100 ul
EUR 369.6

Cytokeratin-18 Rabbit pAb
A1022-200ul 200 ul
EUR 550.8

Cytokeratin-18 Rabbit pAb
A1022-20ul 20 ul
EUR 219.6

Cytokeratin-18 Rabbit pAb
A1022-50ul 50 ul
EUR 267.6

Cytokeratin 19 Protein
20-abx261011
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 16 Protein
20-abx261285
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 19 Protein
20-abx261720
  • EUR 4236.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 20 Protein
20-abx261929
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 17 Protein
20-abx261959
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 Protein
20-abx261980
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 20 Protein
20-abx261981
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 14 Protein
20-abx262029
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 Protein
20-abx262306
  • EUR 393.60
  • EUR 7108.80
  • EUR 276.00
  • 10 ug
  • 1 mg
  • 2 µg

Cytokeratin 14 Protein
20-abx262842
  • EUR 7676.40
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 protein
30R-AC039 250 ug
EUR 817.2
Description: Purified recombinant Human Cytokeratin 18 protein

Cytokeratin 19 protein
30R-AC040 100 ug
EUR 495.6
Description: Purified recombinant Human Cytokeratin 19 protein

Cytokeratin 8 protein
30R-AC041 100 ug
EUR 501.6
Description: Purified recombinant Human Cytokeratin 8 protein

cytokeratin 20 Peptide
43-166P 0.1 mg
EUR 405.6

cytokeratin 20 Peptide
43-167P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide
43-484P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide
43-491P 0.1 mg
EUR 405.6

Cytokeratin-9 Rabbit pAb
A10119-100ul 100 ul
EUR 369.6

Cytokeratin-9 Rabbit pAb
A10119-200ul 200 ul
EUR 550.8

Cytokeratin-9 Rabbit pAb
A10119-20ul 20 ul
EUR 219.6

Cytokeratin-9 Rabbit pAb
A10119-50ul 50 ul
EUR 267.6

Cytokeratin 23 Antibody
20-abx137380
  • EUR 844.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 20 ug
  • 5 ug

Cytokeratin 6A Antibody
abx232215-100ug 100 ug
EUR 610.8

Cytokeratin 10 Antibody
abx139680-01mg 0.1 mg
EUR 427.2

Cytokeratin 18 Antibody
AF7692 200ul
EUR 540

Cytokeratin 18 Antibody
AF7693 200ul
EUR 540

Cytokeratin 17 Antibody
AF7851 200ul
EUR 540

Cytokeratin 19 antibody
10-1210 500 ug
EUR 522
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 7 antibody
10R-1826 100 ul
EUR 483.6
Description: Mouse monoclonal CK7 antibody

Cytokeratin 8 antibody
10R-2766 100 ul
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 19 antibody
10R-6759 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 18 antibody
10R-6766 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 7 antibody
10R-7842 100 ug
EUR 386.4
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 18 antibody
10R-7844 100 ug
EUR 366
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 4 antibody
10R-7960 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 7 antibody
10R-7962 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 7 antibody
10R-7963 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody
10R-7964 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody
10R-7965 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 10 antibody
10R-7966 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 10 antibody
10R-7967 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
10R-7969 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody
10R-7970 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 17 antibody
10R-7971 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody
10R-7972 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
10R-7973 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody
10R-7974 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody
10R-7975 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 6 antibody
10R-7978 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 16 antibody
10R-7979 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 16 antibody

Cytokeratin 8 antibody
10R-7980 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 1 antibody
10R-C155a 200 ug
EUR 705.6
Description: Mouse monoclonal Cytokeratin 1 antibody

Cytokeratin 10 antibody
10R-C157a 100 ug
EUR 766.8
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody
10R-C158a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody
10R-C159a 100 ug
EUR 766.8
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 17 antibody
10R-C160a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody
10R-C161a 50 ug
EUR 566.4
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody
10R-C162a 50 ug
EUR 566.4
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 19 antibody
10R-C163a 100 ug
EUR 793.2
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 20 antibody
10R-C164a 50 ug
EUR 690
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody
10R-C164b 50 ug
EUR 748.8
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody
10R-C164c 50 ug
EUR 1213.2
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 2e antibody
10R-C166a 1 mL
EUR 322.8
Description: Mouse monoclonal Cytokeratin 2e antibody

Cytokeratin 4 antibody
10R-C169a 1 ml
EUR 644.4
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 6 antibody
10R-C172a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 6 antibody
10R-C172b 5 mL
EUR 342
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 7 antibody
10R-C174a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody
10R-C177a 5 mL
EUR 415.2
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody
10R-C177ax 50 ug
EUR 591.6
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 2 antibody
10R-C179a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 2 antibody

Cytokeratin 9 antibody
10R-C196A 1 mL
EUR 550.8
Description: Mouse monoclonal Cytokeratin 9 antibody

Cytokeratin 14 antibody
20R-CP002 100 ul
EUR 676.8
Description: Guinea Pig polyclonal Cytokeratin 14 antibody

Cytokeratin 5 antibody
20R-CP003 100 uL
EUR 654
Description: Guinea Pig polyclonal Cytokeratin 5 antibody

Cytokeratin 2e antibody
22106-100ul 100ul
EUR 468

Cytokeratin 13 antibody
22917-100ul 100ul
EUR 468

Cytokeratin 20 antibody
22920-100ul 100ul
EUR 468

Cytokeratin 5 Antibody
BF0108 200ul
EUR 540

Cytokeratin 5 Antibody
39247-100ul 100ul
EUR 468

Cytokeratin 16 antibody
70R-2869 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 16 antibody
70R-2870 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 16 antibody

Cytokeratin 7 antibody
70R-2930 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 7 antibody raised against the N terminal of KRT7

Cytokeratin 19 antibody
70R-2947 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 23 antibody
70R-2948 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 23 antibody

Cytokeratin 24 antibody
70R-2986 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 24 antibody raised against the middle region of KRT24

Cytokeratin 84 antibody
70R-3002 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 84 antibody raised against the middle region of KRT84

Cytokeratin 19 antibody
70R-3035 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 19 antibody raised against the N terminal of KRT19

Cytokeratin 75 antibody
70R-3038 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the N terminal of KRT75

Cytokeratin 75 antibody
70R-3039 50 ug
EUR 560.4
Description: Rabbit polyclonal Cytokeratin 75 antibody raised against the middle region of KRT75

Cytokeratin 19 Antibody
abx024063-100ug 100 ug
EUR 493.2

Cytokeratin 19 Antibody
BF0197 200ul
EUR 540

Cytokeratin 8 Antibody
BF0606 200ul
EUR 540

Cytokeratin 18 antibody
BF0727 200ul
EUR 540

Cytokeratin 16 Antibody
AF0189 200ul
EUR 420

Cytokeratin 17 Antibody
AF0190 200ul
EUR 420

Cytokeratin 18 Antibody
AF0191 200ul
EUR 420

Cytokeratin 19 Antibody
AF0192 200ul
EUR 420

Cytokeratin 20 Antibody
AF0193 200ul
EUR 420

Cytokeratin 5 Antibody
AF0194 200ul
EUR 420

Cytokeratin 7 Antibody
AF0195 200ul
EUR 420

Cytokeratin 8 Antibody
AF0196 200ul
EUR 420

Cytokeratin 10 Antibody
AF0197 200ul
EUR 420

Cytokeratin 15 Antibody
AF0790 200ul
EUR 420

Cytokeratin 13 Antibody
AF5102 200ul
EUR 420

Cytokeratin 19 Antibody
AF5106 200ul
EUR 420

Cytokeratin 14 Antibody
AF5225 200ul
EUR 420

Cytokeratin 15 Antibody
AF5353 200ul
EUR 420

Cytokeratin 14 Antibody
AF5370 200ul
EUR 420
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Development of a nanobody-based competitive ELISA for efficiently and specifically detecting antibodies against genotype 2 porcine reproductive and respiratory syndrome viruses

Development of a nanobody-based competitive ELISA for efficiently and specifically detecting antibodies against genotype 2 porcine reproductive and respiratory syndrome virusesDevelopment of a nanobody-based competitive ELISA for efficiently and specifically detecting antibodies against genotype 2 porcine reproductive and respiratory syndrome viruses

Porcine reproductive and respiratory syndrome virus (PRRSV) an infection causes appreciable financial loss to the worldwide pig business. Environment friendly detection assay is essential for the prevention of the virus

READ MOREREAD MORE